FGF23 and heart failure: In patients on dialysis, the clinically available allosteric modulators (calcimimetics) of the calcium‐sensing receptor, cinacalcet and etelcalcetide, are used to treat hyperparathyroidism and consistently lower circulating FGF23.168, 169, 170, 171, 172 In secondary analyses of the large and well‐designed EVOLVE (Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events) trial, a >30% reduction in FGF23 in patients randomized to cinacalcet was associated with a reduction in cardiovascular mortality, SCD, and admissions for heart failure.